Literature DB >> 14618278

Growth inhibition of an orthotopic glioblastoma in immunocompetent mice by cationic lipid-DNA complexes.

Robert J Higgins1, Maureen McKisic, Peter J Dickinson, Daniel F Jimenez, Steven W Dow, Linda D Tripp, Richard A LeCouteur.   

Abstract

The effect of a cationic liposome non-coding plasmid DNA complex on the growth of an intracerebral glioblastoma in an immunocompetent syngeneic mouse strain was evaluated. Previous studies of extraneural tumors in mice have demonstrated that such complexes containing plasmid DNA are capable of stimulating a potent Th-1 cytokine immune-mediated response with a dramatic inhibition of tumor growth. A DOTIM-cholesterol cationic liposome complexed to non-coding plasmid DNA (EV-CLDC) was administered intravenously (i.v.) at weekly intervals to 6-week-old male mice of the B6D2F1 strain at either 3, 10 or 17 days post-inoculation (DPI) of 4C8 glioblastoma cells. Tumor growth was monitored by volumetric image analysis obtained from sequential weekly magnetic resonance imaging studies of the brain. Experiments were terminated between 30 to 38 DPI. Terminal tumor volumes calculated from histological sections directly correlated with tumor volumes from corresponding MR images. The EV-CLDC administered at 3 DPI resulted in a statistically significant (P<0.0001) sustained inhibition of tumor growth compared with tumors in mice administered only individual components of the EV-CLDC. The EV-CLDC similarly inhibited growth of longer established glioblastomas. Histopathologic evaluation of terminal tumors did not find any hemorrhage, edema or necrosis in either the EV-CLDC-treated or control tumors. The results indicate that an i.v.-administered EV-CLDC can significantly inhibit the growth of a brain tumor in immunocompetent syngeneic mice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14618278     DOI: 10.1007/s00262-003-0447-y

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  7 in total

1.  An orthotopic, postsurgical model of luciferase transfected murine osteosarcoma with spontaneous metastasis.

Authors:  Joseph L Sottnik; Dawn L Duval; E J Ehrhart; Douglas H Thamm
Journal:  Clin Exp Metastasis       Date:  2010-03-07       Impact factor: 5.150

2.  Prevention of human adenocarcinoma with CpG-ODN in a mouse model.

Authors:  Stephen E Wright; Kathleen A Rewers-Felkins; Nazrul I Chowdhury; Jewel Ahmed; Sanjay K Srivastava
Journal:  Oncol Lett       Date:  2012-08-06       Impact factor: 2.967

3.  A novel vaccine adjuvant for recombinant flu antigens.

Authors:  Stella Chang; John Warner; Lily Liang; Jeff Fairman
Journal:  Biologicals       Date:  2009-03-12       Impact factor: 1.856

4.  Synthetic Poly(L-Glutamic Acid)-conjugated CpG Exhibits Antitumor Efficacy With Increased Retention in Tumor and Draining Lymph Nodes After Intratumoral Injection in a Mouse Model of Melanoma.

Authors:  Qing Ma; Dapeng Zhou; Elizabeth S DeLyria; Xiaoxia Wen; Wei Lu; Prakash Thapa; Chengwen Liu; Dan Li; Roland L Bassett; Willem W Overwijk; Patrick Hwu; Chun Li
Journal:  J Immunother       Date:  2017-01       Impact factor: 4.456

Review 5.  Immunocompetent murine models for the study of glioblastoma immunotherapy.

Authors:  Taemin Oh; Shayan Fakurnejad; Eli T Sayegh; Aaron J Clark; Michael E Ivan; Matthew Z Sun; Michael Safaee; Orin Bloch; Charles D James; Andrew T Parsa
Journal:  J Transl Med       Date:  2014-04-29       Impact factor: 5.531

6.  Prevention of liver tumor formation in woodchucks with established hepatocellular carcinoma by treatment with cationic liposome-DNA complexes.

Authors:  Jeffery Fairman; Katherine H Liu; Stephan Menne
Journal:  BMC Cancer       Date:  2017-03-06       Impact factor: 4.430

Review 7.  Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.

Authors:  Maria B Garcia-Fabiani; Santiago Haase; Andrea Comba; Stephen Carney; Brandon McClellan; Kaushik Banerjee; Mahmoud S Alghamri; Faisal Syed; Padma Kadiyala; Felipe J Nunez; Marianela Candolfi; Antonela Asad; Nazareno Gonzalez; Marisa E Aikins; Anna Schwendeman; James J Moon; Pedro R Lowenstein; Maria G Castro
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.